• Create account
  • Log in
Clinical Guidelines
  • Home
  • About
    • About the clinical guidelines
    • Declaring and dealing with competing interests
    • Frequently asked questions
    • Guideline journal articles
  • CCA guidelines
    • Barrett's Oesophagus
    • Bowel cancer
      • Colorectal cancer
      • Surveillance colonoscopy
    • Endometrial cancer
    • Cervical cancer screening
    • Lung cancer
      • Lung cancer prevention & diagnosis
      • Lung cancer treatment
    • Prostate cancer
      • Advanced prostate cancer
      • PSA testing
    • Sarcoma
    • Skin cancer
      • Melanoma
      • Keratinocyte cancer (non-melanoma)
    • Pain management
    • Archive of CCA guidelines
  • COSA guidelines
    • Adolescents and Young Adult (AYA) guidelines
      • AYA early cancer detection
      • AYA psychosocial management
    • Cancer therapy medication safety
    • Gastroenteropancreatic neuroendocrine tumours
    • Head & neck cancer nutrition
    • Teleoncology
  • Hosted
    • Childhood Brain Tumour or Leukaemia
  • National Cancer Prevention Policy
  • View
  • View form
  • Code
  • History
  • Refresh
  • What links here
  • Related changes
  • Special pages
  • Permanent link
  • Page information
  • Browse properties

Citation:Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, et al 2000

From Cancer Guidelines Wiki
Jump to:navigation, search

Citation


Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000 Nov;164(5):1579-82 Available from: http://www.ncbi.nlm.nih.gov/pubmed/11025708.



Critical appraisals

  • Assign a critical appraisal


Compare quality appraisals for each clinical question

Cited by

  1. Are there differences between the different hormone therapy methods in the pattern and severity of toxicity effects for non metastatic disease?
  2. What is the effect on Quality of Life as measured by validated questionnaires due to androgen ablation (deprivation or blockade) treatment?
  3. What should be done for patients with locally advanced disease who are not suitable candidates for surgery or radiotherapy – primary androgen deprivation at diagnosis or wait until clinical progression (localized or metastatic)?
Retrieved from "https://wiki.cancer.org.au/australiawiki/index.php?title=Citation:Iversen_P,_Tyrrell_CJ,_Kaisary_AV,_Anderson_JB,_Van_Poppel_H,_Tammela_TL,_et_al_2000&oldid=15233"
Cancer Council would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.